Lensar, INC

LENSAR, Inc. has appointed Michael A. Rossi as Interim CFO and scheduled its 2026 annual meeting for August 4, 2026.

LENSAR, Inc. announced first quarter 2026 financial results, showing a slight decrease in total revenue compared to the prior year, primarily due to market disruption from a terminated merger, while recurring revenue saw a 9% increase.

LENSAR, Inc. announced that Chief Financial Officer Thomas R. Staab, II will resign from his position effective May 8, 2026.

LENSAR, Inc. announced fourth quarter and full year 2025 financial results, highlighting significant growth in ALLY system adoption and recurring revenue despite a terminated merger.

LENSAR and Alcon have mutually agreed to terminate their merger agreement due to anticipated U.S. regulatory challenges, with LENSAR retaining a $10 million deposit.

LENSAR, Inc. amended its previous filing to clarify the terms of a $9.2 million revolving credit facility secured with Wells Fargo Bank, N.A.

LENSAR, Inc. reports Q1 2026 financial results, highlighting a return to profitability driven by non-operating income from a terminated merger agreement.

LENSAR, Inc. reported a significantly wider net loss in Q3 2025 despite a 6% revenue increase, primarily driven by substantial acquisition-related costs for its pending merger with Alcon and increased warrant liabilities.

LENSAR, Inc. reports increased revenue and reduced net loss for Q2 2025, driven by ALLY System placements, while its acquisition by Alcon faces extended FTC review.

LENSAR, Inc. announces its Q1 2025 financial results, highlighting revenue growth and increased losses, while also addressing the ongoing merger agreement with Alcon.

LENSAR Inc. saw a significant revenue increase in Q3 2024, driven by strong product sales and procedure volume growth.

LENSAR Inc. saw a 5% increase in revenue year-over-year for the second quarter of 2024, driven by increased ALLY System sales and procedure volume, despite a net loss of $9.0 million.

LENSAR, Inc. filed an amendment to its 2025 Annual Report to provide required disclosures regarding directors, executive compensation, and corporate governance.

LENSAR, Inc. reported a 9% increase in total revenue to $58.4 million for fiscal year 2025, alongside continued net losses of $34.3 million and the termination of its merger agreement with Alcon.

LENSAR, Inc. files an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive compensation, security ownership, related transactions, and principal accountant fees.

LENSAR, Inc. saw a 27% increase in revenue for 2024, driven by ALLY System sales and procedure volume, but net losses also increased significantly.

LENSAR, Inc.'s 10-K filing provides a detailed overview of its capital stock, including common and preferred shares, and outlines key regulatory and corporate governance provisions.

LENSAR, Inc. director and major shareholder Todd B. Hammer received an annual grant of 17,421 restricted stock units as part of the company's director compensation program.

LENSAR, Inc. director and major shareholder Thomas B. Ellis received a grant of 17,421 restricted stock units as part of the company's annual director compensation program.

LENSAR, Inc. Principal Accounting Officer Kendra Wong was granted 13,066 restricted stock units as part of an equity incentive.

LENSAR, Inc. Chief Operating Officer Alan B. Connaughton was granted 34,843 restricted stock units as part of an equity incentive plan.

LENSAR, Inc. CEO Nicholas T. Curtis was granted 130,662 restricted stock units as part of his compensation package.

Director Aimee Weisner was granted 17,421 restricted stock units as part of LENSAR, Inc.'s annual non-employee director compensation program.

LENSAR, Inc. announced its 2025 Annual Meeting of Stockholders to be held virtually on December 18, 2025, for the election of Class II Directors and ratification of its independent auditor.

LENSAR, Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on December 18, 2025, to elect Class II directors and ratify its independent accounting firm.

LENSAR, Inc. filed a supplement to its definitive proxy statement for the proposed merger with Alcon Research, LLC, providing additional disclosures to address shareholder demand letters alleging omitted material information.

LENSAR, Inc. and Alcon Research, LLC received a second request for information from the Federal Trade Commission (FTC) regarding their proposed merger, extending the waiting period under the Hart-Scott-Rodino Act.

Alcon Research, LLC is set to acquire LENSAR, Inc. for $14.00 per share in cash plus a contingent value right (CVR) of up to $2.75 per share, pending stockholder approval.

Alcon, a global leader in eye care, intends to acquire LENSAR, a move announced to LENSAR employees on March 24, 2025, with the transaction expected to close in mid-to-late 2025.

An amended Schedule 13D filing reveals that key reporting persons, including North Run Capital and NR-GRI Partners, have entered into a voting agreement to support the merger of LENSAR, Inc. with Alcon Research, LLC.

Brandes Investment Partners, LP has amended its Schedule 13G filing to report beneficial ownership of 1,026,018 common shares in LENSAR, Inc., representing 8.5% of the class.

Brandes Investment Partners, LP has reported a 6.5% beneficial ownership stake in LENSAR, Inc., holding 778,073 common shares as of September 30, 2025.

BlackRock, Inc. has reported a 5.2% beneficial ownership stake in LENSAR, Inc. common stock as of September 30, 2025.

Park West Asset Management LLC, Park West Investors Master Fund, Limited, and Peter S. Park have jointly filed an amended Schedule 13G, disclosing a passive beneficial ownership of 0.7% in LENSAR, INC. as of March 31, 2025.

Nicholas T. Curtis, Chief Executive Officer of LENSAR, Inc., has disclosed a beneficial ownership of 8.5% of the company's common stock as of March 31, 2025, totaling 1,023,482 shares.

Dimensional Fund Advisors LP has filed an amended Schedule 13G, reporting a 4.1% beneficial ownership stake in LENSAR Inc. as of March 31, 2025.